FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2565921615> ?p ?o ?g. }

• W2565921615 abstract "441 Background: Some patients (pt) with metastatic renal cell carcinoma (mRCC) have an indolent course. Treatment toxicities can worsen quality of life. Active surveillance (AS) in paucisymptomatic pts is an option often used but few data is available. Our aim is to analyze the impact of initial AS in a sequential therapy strategy in terms of overall survival (OS). Methods: Data frompt diagnosed with mRCC from January 2005 to December 2013 in 3 centres of Spain were retrospectively analyzed. AS subgroup was defined as pt with ≥6 months (m) between diagnosis and first-line (L) treatment (tto) start. A descriptive analysis and median OS (mOS) were performed comparing pt with or without AS (AS vs. tto <6m). OS curve and medians were estimated using Kaplan Meier Method. A multivariate cox regression analyses with different prognostic factors was also realized. Results: From a cohort of 277 pt with mRCC, 69 pt (25%) were on initial AS and 208 pts on tto <6m (75%). Median time on observation until systemic tto was started on pt on AS was 14 m 95%CI (17.6-26.02). Pt characteristics of AS vs tto <6 m were: median age 63/60; males 70/72%; histology: 94/76% clear cell, 3/12% papillar, 0/4% chromophob; M1 at diagnosis: 22/48%; prognosis (Heng risk criteria): 0/17.% poor, 38.5/57% intermediate, 61.5/25% good; prior nephrectomy: 93/73%; number of metastatic locations (loc): 87/68% ≤2 loc, 12.5/32.5% ≥3 loc; lines of treatment: first L 46/53%, second L 38/23%, and third L 16/24%. When comparing exposure in months to each tto L, pt on AS had longer period of tto in second L (10.06/4.14 m, p=0.014). mOS were: 62 m 95%CI (52.97-71.03) vs. 22 m 95% CI (19.87-24.12) for AS/tto <6 m respectively (p<0.001) with statistical significance after multivariate analysis (Cox regression, HR=0.39; 95% CI, 0.25-0.63). Factors that independently influence on OS were: ≥2 M1 sites and papillar histology, negatively, and prior nephrectomy and >1 year from diagnosis to M1, positively. Conclusions: Our results suggest that AS before starting first L of tto is not a detrimental action in a selected population of mRCC pt with good risk characteristics allowing them to remain free of therapy’s toxicity during a long time period." @default.
• W2565921615 created "2017-01-06" @default.
• W2565921615 creator A5011071446 @default.
• W2565921615 creator A5025563724 @default.
• W2565921615 creator A5032577731 @default.
• W2565921615 creator A5039696593 @default.
• W2565921615 creator A5055824195 @default.
• W2565921615 creator A5055848565 @default.
• W2565921615 creator A5059645677 @default.
• W2565921615 creator A5060467306 @default.
• W2565921615 creator A5066412365 @default.
• W2565921615 creator A5079984186 @default.
• W2565921615 creator A5089518617 @default.
• W2565921615 creator A5089740716 @default.
• W2565921615 date "2015-03-01" @default.
• W2565921615 modified "2023-10-17" @default.
• W2565921615 title "Active surveillance in asymptomatic or minimally symptomatic renal cell carcinoma: Retrospective analyses of a cohort of three oncological centers from Spain." @default.
• W2565921615 doi "https://doi.org/10.1200/jco.2015.33.7_suppl.441" @default.
• W2565921615 hasPublicationYear "2015" @default.
• W2565921615 type Work @default.
• W2565921615 sameAs 2565921615 @default.
• W2565921615 citedByCount "0" @default.
• W2565921615 crossrefType "journal-article" @default.
• W2565921615 hasAuthorship W2565921615A5011071446 @default.
• W2565921615 hasAuthorship W2565921615A5025563724 @default.
• W2565921615 hasAuthorship W2565921615A5032577731 @default.
• W2565921615 hasAuthorship W2565921615A5039696593 @default.
• W2565921615 hasAuthorship W2565921615A5055824195 @default.
• W2565921615 hasAuthorship W2565921615A5055848565 @default.
• W2565921615 hasAuthorship W2565921615A5059645677 @default.
• W2565921615 hasAuthorship W2565921615A5060467306 @default.
• W2565921615 hasAuthorship W2565921615A5066412365 @default.
• W2565921615 hasAuthorship W2565921615A5079984186 @default.
• W2565921615 hasAuthorship W2565921615A5089518617 @default.
• W2565921615 hasAuthorship W2565921615A5089740716 @default.
• W2565921615 hasConcept C126322002 @default.
• W2565921615 hasConcept C141071460 @default.
• W2565921615 hasConcept C143998085 @default.
• W2565921615 hasConcept C167135981 @default.
• W2565921615 hasConcept C2777472916 @default.
• W2565921615 hasConcept C2777910003 @default.
• W2565921615 hasConcept C3019894029 @default.
• W2565921615 hasConcept C38180746 @default.
• W2565921615 hasConcept C50382708 @default.
• W2565921615 hasConcept C71924100 @default.
• W2565921615 hasConcept C72563966 @default.
• W2565921615 hasConceptScore W2565921615C126322002 @default.
• W2565921615 hasConceptScore W2565921615C141071460 @default.
• W2565921615 hasConceptScore W2565921615C143998085 @default.
• W2565921615 hasConceptScore W2565921615C167135981 @default.
• W2565921615 hasConceptScore W2565921615C2777472916 @default.
• W2565921615 hasConceptScore W2565921615C2777910003 @default.
• W2565921615 hasConceptScore W2565921615C3019894029 @default.
• W2565921615 hasConceptScore W2565921615C38180746 @default.
• W2565921615 hasConceptScore W2565921615C50382708 @default.
• W2565921615 hasConceptScore W2565921615C71924100 @default.
• W2565921615 hasConceptScore W2565921615C72563966 @default.
• W2565921615 hasLocation W25659216151 @default.
• W2565921615 hasOpenAccess W2565921615 @default.
• W2565921615 hasPrimaryLocation W25659216151 @default.
• W2565921615 isParatext "false" @default.
• W2565921615 isRetracted "false" @default.
• W2565921615 magId "2565921615" @default.
• W2565921615 workType "article" @default.